September 23, 2020
Equaly announces to be awarded a Walloon Region subsidy for the therapy of orphan diseases
A subsidy of €2.8 million over a period of 3 years will be devoted to the development of novel enzyme replacement therapies for the treatment of both Fabry and Pompe diseases, as well as novel approaches for gene therapy of such diseases.
Fabry and Pompe diseases are two examples of lysosomal storage diseases due to a lack of a functional enzyme essential to glycogen degradation. Such diseases are lethal in their full expression, but are also associated to a number of neurodegenerative syndromes in later life.
The production of non-immunogenic forms of specific enzymes for replacement therapy and of non-immunogenic variants of viral vectors required for gene therapy, according to Equaly’s proprietary technology, should lead to substantial benefit for patients, if not to a cure for such diseases. “